# A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

> **NCT04924192** · PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Advanced Lung Carcinoma

## Interventions

- **DRUG:** TQB3616 capsules
- **DRUG:** Anlotinib Hydrochloride capsules
- **DRUG:** Irinotecan Hydrochloride for Injection

## Key facts

- **NCT ID:** NCT04924192
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-18
- **Primary completion:** 2022-09-27
- **Final completion:** 2022-10-10
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924192, "A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04924192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*